In support of this, systemic vaccination with particles carrying mRNA has recently been shown to yield impressive responses to neo-epitope vaccination in preclinical and clinical studies29,30 and systemically injected liposomes carrying OVA antigen has been used to prime endogenous anti-tumor CD8+ T cells in preclinical studies31. The gene discussed is CD8A; the disease is neoplasm.